Project Grant R01AI198218
Award Date 7/23/26
Completion Date 6/30/31
Dollars Obligated $865K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $772,010 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct mechanistic studies of combination adjuvants in B cell memory establishment. The research examines how three adjuvants formulated together in a vaccine—an NKT cell agonist, a TLR7 agonist, and a QB virus-like particle (VLP)—cooperate to produce high-affinity protective anti-bacterial glycan...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $1.097 million on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop germline-targeted HIV vaccines using membrane ENV liposomes designed to elicit broadly neutralizing antibodies against the membrane-proximal external region (MPER) of the HIV envelope glycoprotein. The research program uses a vaccine platform (membrane ENV liposomes) that displays...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $552,000 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct functional characterization of dendritic cell heterogeneity for T cell-inducing immunotherapies. The research addresses vaccine development for intracellular pathogens including HIV/AIDS and malaria by investigating the distinct roles of type 1 and type 2 conventional dendritic cells in...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the Scripps Research Institute $937,343 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research optimizing vaccine-elicited cross-neutralizing antibody responses targeting the HIV envelope (Env) trimer apex to inform broadly neutralizing antibody (BnAb) development for...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $276,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate HIV-1 envelope-C3D constructs on nanoparticles for structure, function, and immunogenicity. Scripps will assess ENV-C3D fusion candidates carrying two and three copies of C3D domains per GP160 subunit (with or without Fc domain) in C57BL/6 and alloy mice. The research will measure germinal...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Scripps Research Institute $897,277 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct structural and functional research on monkeypox virus entry mechanisms and neutralizing antibody responses. The work integrates antibody isolation from mpox convalescents, vaccine recipients, and a human antibody phage...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $511,531 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance HIV vaccine development using a lipid nanodisc platform. The project, designated R01AI192143, addresses challenges in engineering transmembrane HIV envelope glycoprotein (ENV) vaccine candidates by incorporating them into stable lipid nanodiscs using membrane scaffold proteins and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scripps Research Institute a $506,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 9, 2025, with a completion date of June 30, 2027. The award supports the development of high-throughput technologies for generating and screening small interfering RNA (siRNA)-peptide conjugates designed to improve delivery efficiency for viral infection...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $3.679 million on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop self-assembling protein nanoparticles presenting stabilized hemagglutinin, neuraminidase, and M2E antigens for universal influenza vaccine development. The research addresses the structural and immunological challenges of creating a vaccine effective against both seasonal and pandemic...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $919,363 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular mechanisms governing plasma cell longevity and the establishment of long-lived plasma cells (LLPCs) at mucosal surfaces and bone marrow. The research addresses why current influenza vaccines require annual boosters by examining how plasma cells generated during viral...